CG Oncology (CGON) Fundamental Analysis: Revenue, Earnings & Valuation

4.28 / 10

Netural

Fundamental rating is Neutral with a 4.3/10 score. Strengths include a high interest coverage (35.1) and favorable Asset‑MV, while inventory turnover is decent. However, revenue growth rates are extreme and liabilities are high, making the case defensive and average.

Analysis Checks(6/10)

Revenue-MV

Value-5.09

Score1/3

Weight24.33%

1M Return4.09%

Total operating revenue (YoY growth rate %)

Value254.70

Score1/3

Weight-1.92%

1M Return-0.38%

Inventory turnover ratio

Value5.94

Score2/3

Weight-5.59%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value79.09

Score0/3

Weight-20.70%

1M Return-4.96%

PB-ROE

Value2.93

Score2/3

Weight45.70%

1M Return7.29%

Long-term debt to working capital ratio (%)

Value0.01

Score2/3

Weight-1.73%

1M Return-0.35%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-5.68%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value254.70

Score1/3

Weight-1.51%

1M Return-0.30%

Cost of sales ratio (%)

Value115.02

Score2/3

Weight-5.37%

1M Return-1.13%

Asset-MV

Value-0.55

Score2/3

Weight72.46%

1M Return11.12%

Is CGON fundamentally strong?

CGON scores 4.28/10 on fundamentals and holds a Fair valuation at present. Backed by its -21.67% ROE, -3985.02% net margin, -33.89 P/E ratio, 7.25 P/B ratio, and -47.52% earnings growth, these metrics solidify its Netural investment rating.